Melatonin: Clinical relevance

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 17, Issue 2, 2003, Pages 273-285

  Reiter, Russel J ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Cancer; Circadian rhythms; Jet lag; Light:dark cycle; Melatonin; Oxidative stress; Pineal gland; Sleep

Indexed keywords

ANTINEOPLASTIC AGENT; ERYTHROPOIETIN; FREE RADICAL; INDOLE; IRON; MELATONIN; MELATONIN RECEPTOR;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; CANCER; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL PROTECTION; CHRONOBIOLOGY; CIRCADIAN RHYTHM; DEGENERATIVE DISEASE; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG TOXICITY; ERYTHEMA; EVIDENCE BASED MEDICINE; FIBROMYALGIA; HORMONAL REGULATION; HORMONE ACTION; HORMONE METABOLISM; HORMONE RELEASE; HORMONE SYNTHESIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INSOMNIA; ISCHEMIA; JET LAG; LIGHT DARK CYCLE; LIGHT EXPOSURE; MANIA; NERVE CELL NETWORK; NEWBORN SEPSIS; NONHUMAN; OXIDATIVE STRESS; PARKINSONISM; PINEAL BODY; PINEAL GLAND FUNCTION; QUALITY OF LIFE; REM SLEEP DEPRIVATION; REPERFUSION INJURY; RESTLESS LEGS SYNDROME; RETINA; REVIEW; SCHISTOSOMIASIS; SIGNAL TRANSDUCTION; SLEEP; SLEEP DISORDER; SUPRACHIASMATIC NUCLEUS; TARDIVE DYSKINESIA; ANTINEOPLASTIC ACTIVITY; DRUG EFFECT;

EID: 0037700244     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-690X(03)00016-2     Document Type: Review

References (64)

1. Lerner AB, Case JD, Takahashi Y et al. Isolation of melatonin, the pineal gland factor that lightens melanocytes. Journal of the American Chemical Society 1958; 80: 2587.
2. Lerner AB, Case JD & Heinzelmann RV. Structure of melatonin. Journal of the American Chemical Society 1959; 81: 6084-6085.
3. Malpaux B, Migaud M, Tricoire H & Chemineau P. Biology of mammalian photoperiodism and the critical role of the pineal gland and melatonin. Journal of Biological Rhythms 2001; 16: 336-347.
4. Reiter RJ. The melatonin rhythm: Both a clock and a calendar. Experientia 1993; 49: 654-664.
5. Guerrero JM & Reiter RJ. Melatonin-immune system relationships. Current Topics in Medicinal Chemistry 2002; 2: 167-180.
6. Dubocovich ML, Mansana MI & Benloucif S. Molecular pharmacology and function of melatonin receptor subtypes. Advances in Experimental Medicine and Biology 1999; 460: 181-190.
7. Blask DE, Sauer LA & Dauchy RT. Melatonin as a chronobiotic/anti-cancer agent: Cellular, biochemical and molecular mechanisms of action and their implications for circadian-based cancer therapy. Current Topics in Medicinal Chemistry 2002; 2: 113-132.
8. Reiter RJ, Tan DX, Sainz RM et al. Melatonin: Reducing the toxicity and increasing the efficacy of drugs. Journal of Pharmacy and Pharmacology 2002; 54: 1299-1321.
9. Tan DX, Reiter RJ, Manchester LC et al. Chemical and physical properties and potential mechanisms: Melatonin as a broad-spectrum antioxidant and free radical scavenger. Current Topics in Medicinal Chemistry 2002; 2: 181-198.
10. Reiter RJ. The mammalian pineal gland as an end organ of the visual system. In Wettenberg L (ed.) Light and Biological Rhythms in Man. Oxford: Pergamon Press, 1993, pp 145-150.
11. Brainard GC, Hanifen JP, Rollog MD et al. Human melatonin regulation is not mediated by the three cone photopic visual system. Journal of Clinical Endocrinology and Metabolism 2001; 86: 433-436.
12. Foster RG & Hankins MW. Non-rod, non-cone photoreception in the vertebrates. Progress in Retina and Eye Research 2002; 21: 507-527.
13. Cassone VM & Nateson AK. Time and time again: The phylogeny of melatonin as a transducer of biological time. Journal of Biological Rhythms 1997; 12: 489-497.
14. Reiter RJ. Pineal melatonin: Cell biology of its synthesis and of its physiological interactions. Endocrine Reviews 1991; 12: 151-180.
15. Klein DC, Coon SL, Rosenboom PH et al. The melatonin rhythm-generating enzyme: Molecular regulation of serotonin N-acetyltransferase in the pineal gland. Recent Progress in Hormone Research 1997; 52: 307-358.
16. Arendt J. Melatonin, circadian rhythms and sleep. New England Journal of Medicine 2000; 343: 1114-1116.
17. Tricoire H, Lacotelli A,Chemineau P & Malpaux B. Melatonin enters the cerebrospinal fluid through the pineal recess. Endocrinology 2002; 143: 84-90.
18. Wehr TA. Photoperiodism in humans and other primates: Evidence and implications. Journal of Biological Rhythms 2001; 16: 348-364.
19. Reiter RJ. Good light and bad: Some physiological consequences of the electromagnetic spectrum. In Hocevar A, Crepinsek Z & Kaifez-Bogataj L (eds) Biometerology, vol. 2, pt. 2. Ljublijiana: CIP Press, 1997, pp 112-123.
20. Reiter RJ. The aging pineal gland and its physiological consequences. BioEssays 1992; 14: 169-175.
21. Sack RL, Lewy AJ, Vollmer VM & Singer CM. Human melatonin production decreases with age. Journal of Pineal Research 1986; 3: 379-388.
22. Tan DX, Manchester LC, Reiter RJ et al. A novel melatonin metabolite, cyclic 3-hydroxymelatonin: A biomarker of melatonin interaction with hydroxyl radicals. Biochemical and Biophysical Research Communications 1998; 253: 614-620.
23. Tan DX, Manchester LC, Hardeland R et al. Melatonin: A hormone, a tissue factor, an autocoid, a paracoid and a antioxidant vitamin. Journal of Pineal Research 2003; 34: 75-78.
24. Reppert SM. Melatonin receptors: Molecular biology of a new family of G protein-coupled receptors. Journal of Biological Rhythms 1997; 12: 528-531.
25. Dubocovich ML, Cardinali DP, Guardiola-Lemaitre RM, et al. Melatonin receptors. IUPHAR Compendium of Receptor Characterization and Classification. London: IUPHAR Media, 1998. pp. 187-193.
26. McArthur AJ, Hunt AE & Gillette MV. Melatonin action and signal transduction in the rat suprachiasmatic circadian clock: Activation of protein kinase C at dusk and dawn. Endocrinology 1997; 138: 627-634.
27. Morgan PJ. The pars luberalis: The missing link in the photopliodic regulation of prolactin secretion? Journal of Neuroendocrinology 2000; 12: 287-295.
28. Pozo D, Reiter RJ, Calvo JR & Guerrero JM. Inhibition of cerebellar nitric oxide synthase and cyclic GMP production by melatonin via complex formation with calmodulin. Journal of Cellular Biochemistry 1997; 65: 430-442.
29. Garcia-Maurino S, Pozo D, Calvo JR & Guerrero JM. Correlation between nuclear melatonin reception expression and enhanced cytokine production in human lymphocytic and monocytic cell lines. Journal of Pineal Research 2000; 29: 129-137.
30. Reiter RJ, Tan DX, Osuna C & Gitto E. Actions of melatonin in the reduction of oxidative stress: A review. Journal of Biomedical Science 2000; 7: 444-458.
31. Allegra M, Reiter RJ, Tan DX et al. The chemistry of melatonin's interaction with reactive species. Journal of Pineal Research 2003; 34: 1-10.
32. Dubocovich ML, Benloucif S & Masana MI. Melatonin receptors in the mammalian suprachiasmatic neucleus. Behavioral Brain Research 1996; 73: 141-147.
33. Parry BL. Jet lag: Minimizing its effects with critically timed bright light and melatonin administration. Journal of Molecular Microbiology and Biotechnology 2002; 4: 463-466.
34. Dijk DJ & Cajochen C. Melatonin and the circadian regulation of sleep initiation, consolidation, structure, and the sleep, EEG. Journal of Biological Rhythms 1997; 12: 636-643.
35. Kennaway DJ & Wright H. Melatonin and circadian rhythms. Currents Topics in Medicinal Chemistry 2002; 2: 199-209.
36. Gilbert SS, Van Den Heuvel CJ & Dawson D. Daytime melatonin and temazepam in young adult humans: Equivalent effects on sleep latency and body temperature. Journal of Physiology (London) 1999; 514: 903-914.
37. Cardinali DP, Bursco LI, Floret SP & Furio AM. Melatonin in sleep disorders and jet lag. Neuroendocrinology Letters 2002; 23(Suppl. 1): 9-13.
38. Sauer LA, Dauchy RT & Blask DE. Polyunsaturated fatty acids, melatonin and cancer progression. Biochemical Pharmacology 2001; 61: 1455-1462.
39. Lissoni P. Is there a role for melatonin in supportive care? Supportive Cancer Care 2002; 10: 110-116.
40. Molis TM, Spriggs LL & Hill SM. Modulation of oestrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Molecular Endocrinology 1994; 8: 1681-1690.
41. Karbownik M, Lewinski A & Reiter RJ. Anti-carcinogenic actions of melatonin which involve antioxidative processes: Comparison with other antioxidants. International Journal of Biochemistry and Molecular Biology 2001; 33: 735-753.
42. Maestroni CJM. The immunoneuroendocrine role of melatonin. Journal of Pineal Research 1993; 14: 1-10.
43. Liu F, Ng TB & Fung MC. Pineal indoles stimulate the gene expression of immunomodulating cytokines. Journal of Neural Transmission 2001; 108: 397-405.
44. 1 and thymulin concentrations: Observations in rats and humans. Journal of Neuroimmunobiology 2000; 103: 108-188.
45. Sainz RM, Mayo JC, Reiter RJ et al. Melatonin regulates glucocorticoid receptor: An answer to its antiapoptic action in thymus. FASEB J 2000; 13: 1547-1556.
46. Garcia-Maurino, S., Gonzalez-Haba, MG, Calvo, JR, et al. Involvement of molecular binding sites for melatonin in the regulation of, IL-2 and, IL-6 production by human blood mononuclear cells. Journal of Neuroimmunology 1998; 92: 76-84.
47. Calvo JR, Guerrero JM, Osuna C et al. Melatonin triggers Crohn's disease symptoms. Journal of Pineal Research 2002; 32: 277-278.
48. Tan DX, Chen LD, Poeggeler B et al. Melatonin: A patent, endogenous hydroxyl radical scavenger. Endocrine Journal 1993; 1: 57-63.
49. Reiter RJ, Tan DX, Manchester LC & Qi W. Biochemical reactivity of melatonin with reactive oxygen and nitrogen species. Cell Biochemistry and Biophysics 2001; 34: 237-256.
50. Urata Y, Honma S, Goto S et al. Melatonin induces gamma-glutymlcysteine synthetase mediated by activator protein-1 in human vascular endothelial cells. Free Radical Biology and Medicine 1999; 27: 838-847.
51. Acuña-Castroviejo D, Martin M, Macias M et al. Melatonin, mitochondria and cellular bioenergetics. Journal of Pineal Research 2001; 30: 65-74.
52. Reiter RJ. Oxidative damage in the central nervous system: Protection by melatonin. Progress in Neurobiology 1998; 56: 359-384.
53. Reiter RJ, Tan DX, Manchester LC & Calvo JR. Antioxidative capacity of melatonin. In Cadenas E & Packer L (eds) Handbook of Antioxidants, 2nd ed. New York: Marcell Dekker, 2002, pp 565-613.
54. Pappolla MA, Chyan YJ, Poeggeler B et al. An assessment of the antioxidant and antiamyloidogenic properties of melatonin: Implications for Alzheimer's disease. Journal of Neural Transmission 2000; 107: 203-231
55. Antolin I, Mayo JC, Sainz RM et al. Protective effect of melatonin in a chronic experimental model of Parkinson's disease. Brain Research 2002; 943: 163-173.
56. Brusco LI, Marquez M & Cardinali DP. Monozygotic twins in Alzheimer's disease treated with melatonin: Case report. Journal of Pineal Research 1998; 25: 260-263.
57. Brusco LI, Marquez M & Cardinali DP. Melatonin treatment stabilizes chronobiologic and cognitive symptoms in Alzheimer's disease. Neuroendocrinology Letters 2000; 21: 39-42.
58. Cohen-Mansfield J, Garfinkel D & Lipson S. Melatonin for treatment of sundowning in elderly persons with dementia-a preliminary study. Archives of Gerontology and Geriatrics 2000; 31: 65-76.
59. Gitto E, Karbownik M, Reiter RJ et al. Effects of melatonin treatment in septic newborns. Pediatric Research 2001; 50: 756-760.
60. Fulia F, Gitto E, Cuzzocrea S et al. Increased levels of malondialdehyde and nitrite/nitrate in the blood of asphyxiated newborns: Reduction by melatonin. Journal of Pineal Research 2001; 31: 343-349.
61. Bangha E, Elsner P & Kistler GS. Suppression of UV-induced erythema by topical treatment with melatonin (N-acetyl-5-methoxytryptamine). A dose response study. Archives of Dermatological Research 1996; 288: 522-526.
62. Shamir E, Barak Y, Shalman I et al. Melatonin treatment for tardive dyskinesia: A double-blind, placebo-controlled, cross-over study. Archives of General Psychiatry 2001; 58: 1049-1052.
63. Herrera J, Nava M, Romero F & Rodriguez-Iturbe B. Melatonin prevents oxidative stress resulting from iron and erythropoietin administration. American Journal of Kidney Diseases 2001; 37: 750-757.
64. Benot S, Goberna R, Reiter RJ et al. Physiological levels of melatonin contribute to the antioxidant capacity of human serum. Journal of Pineal Research 1999; 27: 59-64.